Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy

Keyphrases

• Targeted Therapy 100%
• Chronic Lymphocytic Leukemia 100%
• Leukemia Therapy 100%
• Chemoimmunotherapy 100%
• Personalized Therapy 100%
• Novel Agents 40%
• Patient Selection 20%
• Highly Active 20%
• Adverse Effects 20%
• Patient Characteristics 20%
• Biological Basis 20%
• Anti-apoptotic Proteins 20%
• Novel Therapeutics 20%
• B-cell Lymphoma 2 (Bcl-2) 20%
• Phosphoinositide 3-kinase (PI3K) 20%
• Kinase Inhibitor 20%
• Therapy Types 20%
• Continued Use 20%
• Traditional Treatment 20%
• Therapy Approaches 20%
• Armamentarium 20%
• Anti-CD20 Antibody 20%
• Treatment Algorithm 20%
• Traditional Therapy 20%
• Individual Risk Factors 20%
• Personalized Approach 20%
• Treatment Preferences 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Lymphatic Leukemia 100%
• Antiapoptotic 20%
• Rituximab 20%
• Phosphotransferase Inhibitor 20%

Nursing and Health Professions

• Phosphotransferase Inhibitor 20%